This content is provided by Chambers. Learn more about our methodology
What the team is known for The preferred choice for many when it comes to life sciences matters, drawing from a pool of regulatory and industry experts to advise on growth investment transactions. Wider sector expertise also covers technology and cleantech. Regularly works with investors and emerging companies on venture financings as well as advising on post-investment management operations. Well positioned to handle cross-border investments involving US and European entities.
Strengths A client comments: "It's an excellent firm. I've been very impressed by their capabilities and professionalism."
Another reports: "They have an ability to be commercial, and the advice they give is good."
Work highlights Advised BenevolentAI on an investment of USD90 million by Temasek.
James Gubbins maintains an excellent venture capital practice as part of a broader offering incorporating expertise in M&A and IPOs. His work focuses on deals in the life sciences and technology sectors.
Louise Nash possesses deep experience in the venture capital space, and represents a client base of investors and early-stage companies in their transactional activity. She is well versed in the technology and media sectors.